Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the…

Randomized trialAge and ageing· Jul 2026

Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.

Haoxin Tina Zheng, Aung Zaw Zaw Phyo, Zimu Wu … Joanne Ryan

GeriatricsRandomized trialClinical practiceQ1IF 6.0

Low-dose aspirin did not reduce loss of healthspan in older adults

Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.

Haoxin Tina Zheng … Joanne Ryan

Age and ageing · Jul 2026 · Q1 in General Medicine

Background

Inflammation is a shared pathogenic pathway underlying multiple chronic conditions and contributes to a loss of healthspan.

Purpose

This study aimed to evaluate the effect of low-dose aspirin on the loss of healthspan in older individuals.

Methods

ASPirin in Reducing Events in the Elderly (ASPirin in Reducing Events in the Elderly) was a double-blind, placebo-controlled, randomised trial assessing the effect of daily low-dose aspirin for primary prevention.

n = 5835 participants

Results

aspirin made no difference to healthspan risk

HR 0.98 (95% CI 0.92 to 1.05)

CI crosses the null - not significant

More results

A total of 19 114 participants were followed for a median of 4.7 years, 5835 participants (30.5%) experienced a loss of healthspan.

The rate of healthspan loss was 82.1 and 82.7 events per 1000 person-years in the aspirin and placebo groups, respectively.

“

Conclusion

Low-dose aspirin had no effect on the rate of loss of healthspan among older community-dwelling adults. Future studies should explore lifestyle and behavioural interventions to extend healthspan.

Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.

Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.

Related papers